These enticing features have led to the suggestion that combined treatment with basal insulin and GLP1-RA warrants consideration when first initiating injectable therapy in patients with longstanding T2DM and sub-optimal glycemic control on oral medications8. Here, GLP1R is linked to type 2 diabetes mellitus.